Relius Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 8 Year, 28 Days
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 18.66%
(FY 2023)
- Ebitda 18.66%
(FY 2023)
- Net Worth -51.87%
(FY 2023)
- Total Assets 27.90%
(FY 2023)
About Relius Lifesciences
The Corporate was formerly known as Espee Injectables Private Limited. The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Swapnil Shah, Anar Shah, Roma Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299GJ2016PTC094454
- Company No.
094454
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Nov 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Relius Lifesciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arpit Shah  | Director | 21-Nov-2016 | Current |
| Swapnil Shah | Director | 21-Nov-2016 | Current |
| Anar Shah | Director | 30-Jul-2020 | Current |
| Roma Shah | Director | 21-Nov-2016 | Current |
Financial Performance and Corporate Structure Insights of Relius Lifesciences.
Relius Lifesciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 18.66% increase in profit. The company's net worth observed a substantial decline by a decrease of 51.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Relius Lifesciences?
In 2023, Relius Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Senores Pharmaceuticals LimitedActive 6 years 11 monthsSwapnil Shah and Arpit Shah are mutual person
Remus Pharmaceuticals LimitedActive 9 years 3 monthsSwapnil Shah, Anar Shah and 2 more are mutual person
Ratnatris Pharmaceuticals Private LimitedActive 18 years 11 monthsSwapnil Shah and Arpit Shah are mutual person
- Renosen Pharmaceuticals Private LimitedActive 5 years 7 months
Swapnil Shah and Anar Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Relius Lifesciences?
Unlock and access historical data on people associated with Relius Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Relius Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Relius Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
